Uniqure (QURE) Lifted to “Strong-Buy” at BidaskClub

Uniqure (NASDAQ:QURE) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday.

Several other research analysts have also recently issued reports on QURE. Zacks Investment Research raised Uniqure from a “sell” rating to a “hold” rating in a report on Thursday, January 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $65.00 price target on shares of Uniqure in a report on Thursday, November 15th. Wells Fargo & Co upped their price target on Uniqure from $51.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, February 28th. HC Wainwright reaffirmed a “buy” rating on shares of Uniqure in a report on Tuesday, February 26th. Finally, B. Riley upped their price target on Uniqure from $50.00 to $72.00 and gave the company a “buy” rating in a report on Friday, November 16th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $66.20.

QURE opened at $63.55 on Wednesday. The company has a market capitalization of $2.44 billion, a price-to-earnings ratio of -27.16 and a beta of 1.07. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.85 and a quick ratio of 11.85. Uniqure has a 1-year low of $20.29 and a 1-year high of $67.93.

Uniqure (NASDAQ:QURE) last posted its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.08. Uniqure had a negative return on equity of 47.73% and a negative net margin of 738.25%. On average, analysts predict that Uniqure will post -2.8 EPS for the current fiscal year.

In other Uniqure news, Director David Schaffer sold 7,500 shares of the business’s stock in a transaction on Thursday, January 17th. The shares were sold at an average price of $30.71, for a total transaction of $230,325.00. Following the sale, the director now directly owns 43,701 shares of the company’s stock, valued at approximately $1,342,057.71. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Christian Klemt sold 5,739 shares of the business’s stock in a transaction on Thursday, January 3rd. The shares were sold at an average price of $27.91, for a total transaction of $160,175.49. Following the sale, the insider now directly owns 40,000 shares in the company, valued at $1,116,400. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,014 shares of company stock worth $1,454,779. Company insiders own 1.56% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Redmile Group LLC raised its stake in Uniqure by 1.0% during the 3rd quarter. Redmile Group LLC now owns 1,639,900 shares of the biotechnology company’s stock valued at $59,676,000 after purchasing an additional 15,500 shares during the period. Federated Investors Inc. PA raised its stake in Uniqure by 43.5% during the 3rd quarter. Federated Investors Inc. PA now owns 1,565,600 shares of the biotechnology company’s stock valued at $56,972,000 after purchasing an additional 474,320 shares during the period. 683 Capital Management LLC raised its stake in Uniqure by 10.3% during the 4th quarter. 683 Capital Management LLC now owns 1,085,000 shares of the biotechnology company’s stock valued at $31,270,000 after purchasing an additional 100,900 shares during the period. BlackRock Inc. raised its stake in Uniqure by 3.6% during the 3rd quarter. BlackRock Inc. now owns 481,106 shares of the biotechnology company’s stock valued at $17,507,000 after purchasing an additional 16,680 shares during the period. Finally, RTW Investments LP raised its stake in Uniqure by 7.7% during the 4th quarter. RTW Investments LP now owns 461,837 shares of the biotechnology company’s stock valued at $13,310,000 after purchasing an additional 32,857 shares during the period. 61.16% of the stock is currently owned by institutional investors.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Read More: Moving Average – How it Helps Investors in Stock Selection

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.